DOI: https://doi.org/10.25305/unj.150511

Indices of coagulation hemostasis in patients with hemorrhagic stroke, associated with essential hypertension, after an early recovery period

Oleksandr V. Tkachyshyn

Abstract


Objective: To determine and evaluate indices of coagulation hemostasis in patients with hemorrhagic stroke (HS), associated with essential hypertension (EH), after the early recovery period.

Materials and methods. There were formed 2 groups of patients: the basic group included 94 patients (50 women and 44 men, middle age 54.4  ± 8.8 years old) who experienced HS, associated with EH, 6 months and earlier and had no spontaneous normalization of blood pressure over this period; the comparison group consisted of 104 persons (54 women and 50 men, middle age 53.7  ± 8.9 years old) with EH. They were matched groups by the key indicators. All the above-mentioned patients underwent fasted test of venous blood for detecting coagulation indices.

Results. Determining the mean values of the coagulation parameters in both groups, there was found that the activated partial thromboplastin time (APTT) in the basic group was greater than in the comparison group — 28.345  ± 3.317 s and 26.629 ± 4.601 s, respectively (p<0.05). The patients of the basic group within 6-11 months after HS onset experienced a higher level of APTT (29.410 ± 3.806 s); and the value of thrombin time (TT) was lower than in the comparison group — 21.740 ± 1.691 s and 23.217 ± 5.740, respectively (p <0.05). In the basic group, Claus fibrinogen test showed a direct noticeable correlation (0.502) according to the Chaddock scale with the number of months after the early recovery period after HS.

Conclusions. Hypertensive patients experienced HS have significantly higher value of APTT, indicating that the cascade of hemostasis is slowed down compared with patients with EH without complications. Hypertensive patients experienced HS 6–11 months before have statistically significant greater value of the APTT and lower TT value. In hypertensive patients after HS, there is a direct noticeable correlation between the concentration of Claus fibrinogen in the blood plasma and the number of months after the early recovery period after HS onset.


Keywords


stroke; essential hypertension; fibrinogen; coagulogram

References


1. Mirsaeva GK, Khakimova RA. Anticoagulant and fibrinolytic blood systems in patients with arterial hypertension stage III. Kazan Medical Journal. 2014;95(5):621-625. Russian. https://kazanmedjournal.ru/kazanmedj/article/view/2203

2. Mirsaeva GH, Khakimova RA, Timershina IR. Endothelial dysfunction and vascular-trommbocyte hemostasis in patients with arterial hypertension following hemorrhagic stroke. Astrakhanskiy Meditsinskiy Zhurnal. 2011;6(3):239-240. Russian. https://elibrary.ru/item.asp?id=17733026

3. Mirsaeva GK, Khakimova RA, Timershina IR. Thrombocyte hemostasis disorders in patients with arterial hypertension at different terms after survived hemorrhagic stroke. Kazan Medical Journal. 2015;96(5):722-727. Russian. [CrossRef]

4. Unifikovanyy klinichnyy protokol ekstrenoyi, pervynnoyi, vtorynnoyi (spetsializovanoyi), tretynnoyi (vysokospetsializovanoyi) medychnoyi dopomohy ta medychnoyi reabilitatsiyi «Hemorahichnyy insul' (vnutrishn'omozkova hematoma, anevryzmal'nyy subarakhnoyidal'nyy krovovylyv)». Nakaz Ministerstva okhorony zdorov'ya Ukrayiny 17.04.2014 № 275. [Ukrainian]. http://old.moz.gov.ua/docfiles/dod275_ukp_2014.pdf

5. Malchevska TY. Koahulyatsiyni faktory ryzyku i laboratorni metody yikh otsinky. Vnutrennyaya meditsina. 2007;6(6). Ukrainian. http://www.mif-ua.com/archive/article/3602

6. Appiah D, Schreiner PJ, MacLehose RF, Folsom AR. Association of Plasma γ' Fibrinogen With Incident Cardiovascular Disease: The Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2015 Dec;35(12):2700-6. [CrossRef] [PubMed] [PubMed Central]

7. Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M, Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Ikram MA, Völzke H, Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; PROG-IMT study group. Inflammatory markers and extent and progression of early atherosclerosis: Meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Eur J Prev Cardiol. 2016 Jan;23(2):194-205. [CrossRef] [PubMed] [PubMed Central]

8. Schreiner PJ, Appiah D, Folsom AR. Gamma prime (γ') fibrinogen and carotid intima-media thickness: the Atherosclerosis Risk in Communities study. Blood Coagul Fibrinolysis. 2017 Dec;28(8):665-669. [CrossRef] [PubMed] [PubMed Central]

9. Tkachyshyn OV. Ultrasonic evaluation of hemodynamics and morphology of the major arteries of the neck in patients with essential hypertension associated with hemorrhagic stroke. Ukrainian Neurosurgical Journal. 2018;(2):69-78. Ukrainian. [CrossRef]

10. Zhuk MY, Metelskaya VA, Perova NV, Zhidko NI, Aronov DM, Oganov RG. Disorders of plasma and platelet pathways of hemostasis in patients with arterial hypertension combined with dislipoproteinemia. Russian Journal Of Cardiology. 2003;5(43):11-17. Russian. http://cardio.medi.ru/6630502a.htm

11. Kalz J, ten Cate H, Spronk HM. Thrombin generation and atherosclerosis. J Thromb Thrombolysis. 2014 Jan;37(1):45-55. [CrossRef] [PubMed]

12. Palekar RU, Jallouk AP, Myerson JW, Pan H, Wickline SA. Inhibition of Thrombin With PPACK-Nanoparticles Restores Disrupted Endothelial Barriers and Attenuates Thrombotic Risk in Experimental Atherosclerosis. Arterioscler Thromb Vasc Biol. 2016 Mar;36(3):446-55. [CrossRef] [PubMed] [PubMed Central]


GOST Style Citations






Copyright (c) 2019 Oleksandr V. Tkachyshyn

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.